Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Pfizer Inc (PFE) Price & Performance

MONDELEZ INTERNATIONAL INC Common StockTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

MONDELEZ INTERNATIONAL INC Common Stock vs Pfizer Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $61.85 (market cap $78.85B), while Pfizer Inc trades at $26.28 (market cap $151.73B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.

MDLZPFE
Market Cap
$78.85B$151.73B
Sector
Consumer StaplesHealth
52-Week High
$64.99$28.56
52-Week Low
$51.51$23.60
Enterprise Value
$99.19B$203.22B
Dividend Yield
3.24%6.46%
Volume
29,869,932

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MONDELEZ INTERNATIONAL INC Common Stock

Mondelez International (MDLZ) trades at $61.71, up 0.28% on the day, reflecting steady momentum after a series of earnings beats. The stock exhibits a bullish technical trend, supported by strong moving averages. Fundamentally, the company reported Q2 2026 EPS of $0.73, exceeding estimates, and raised its organic sales outlook for 2026. Revenue growth is solid, though net income margin compression from 2023 peaks remains a watch point. Analyst sentiment is overwhelmingly positive, with a consensus price target of $70.50 implying significant upside.

The outlook for MDLZ is favorable, driven by pricing power, volume growth in emerging markets, and a robust brand portfolio. Key opportunities include market share gains and consistent dividend payments. Primary risks involve exposure to international economic volatility, inflationary cost pressures, and intense competition in the snack food industry. The stock presents a compelling case for growth-oriented investors seeking stability in consumer staples.

Pfizer Inc

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MONDELEZ INTERNATIONAL INC Common Stock

Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.

Read more on MDLZ

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE